529 related articles for article (PubMed ID: 10836293)
21. Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma.
Chui MH; Xing D; Zeppernick F; Wang ZQ; Hannibal CG; Frederiksen K; Kjaer SK; Cope L; Kurman RJ; Shih IM; Wang TL; Vang R
Am J Surg Pathol; 2019 Nov; 43(11):1462-1472. PubMed ID: 31343420
[TBL] [Abstract][Full Text] [Related]
22. Serous and mucinous borderline ovarian tumours: differences in clinical presentation, high-risk histopathological features, and lethal recurrence rates.
Vasconcelos I; Darb-Esfahani S; Sehouli J
BJOG; 2016 Mar; 123(4):498-508. PubMed ID: 26705090
[TBL] [Abstract][Full Text] [Related]
23. Ovarian papillary serous tumors of low malignant potential (serous borderline tumors). A long-term follow-up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma.
Kennedy AW; Hart WR
Cancer; 1996 Jul; 78(2):278-86. PubMed ID: 8674004
[TBL] [Abstract][Full Text] [Related]
24. Early recurrence of ovarian serous borderline tumor as high-grade carcinoma: a report of two cases.
Parker RL; Clement PB; Chercover DJ; Sornarajah T; Gilks CB
Int J Gynecol Pathol; 2004 Jul; 23(3):265-72. PubMed ID: 15213603
[TBL] [Abstract][Full Text] [Related]
25. Classification of Extraovarian Implants in Patients With Ovarian Serous Borderline Tumors (Tumors of Low Malignant Potential) Based on Clinical Outcome.
McKenney JK; Gilks CB; Kalloger S; Longacre TA
Am J Surg Pathol; 2016 Sep; 40(9):1155-64. PubMed ID: 27428735
[TBL] [Abstract][Full Text] [Related]
26. Assessing the landscape of ovarian serous borderline tumors.
Messini I; Doulgeraki T; Chrysanthakis D; Yiannou P; Gavresea T; Papadimitriou C; Panoskaltsis T; Voulgaris Z; Vlachos A; Pavlakis K
Int J Gynecol Cancer; 2019 Mar; 29(3):572-578. PubMed ID: 30659030
[TBL] [Abstract][Full Text] [Related]
27. Serous borderline tumors of the ovary.
Prat J
Adv Clin Path; 1997 Apr; 1(2):97-102. PubMed ID: 10352473
[TBL] [Abstract][Full Text] [Related]
28. Advanced-stage serous borderline tumors of the ovary: a clinicopathological study of 49 cases.
Gilks CB; Alkushi A; Yue JJ; Lanvin D; Ehlen TG; Miller DM
Int J Gynecol Pathol; 2003 Jan; 22(1):29-36. PubMed ID: 12496695
[TBL] [Abstract][Full Text] [Related]
29. A nationwide study of ovarian serous borderline tumors in Denmark 1978-2002. Risk of recurrence, and development of ovarian serous carcinoma.
Hannibal CG; Vang R; Junge J; Frederiksen K; Kurman RJ; Kjaer SK
Gynecol Oncol; 2017 Jan; 144(1):174-180. PubMed ID: 27836204
[TBL] [Abstract][Full Text] [Related]
30. Prognostic factors in patients with ovarian serous low malignant potential (borderline) tumors with peritoneal implants.
Kane A; Uzan C; Rey A; Gouy S; Camatte S; Pautier P; Lhommé C; Haie-Meder C; Duvillard P; Morice P
Oncologist; 2009 Jun; 14(6):591-600. PubMed ID: 19487334
[TBL] [Abstract][Full Text] [Related]
31. [Clinicopathologic analysis of ovarian serous and mucinous borderline tumors].
Zhong C; Yu X; Zhang J; Wei B; Luo B; Sun L; Zhang N; Fu Q
Zhonghua Bing Li Xue Za Zhi; 2001 Aug; 30(4):253-5. PubMed ID: 11758211
[TBL] [Abstract][Full Text] [Related]
32. Pathology of borderline (low malignant potential) ovarian tumours.
Seidman JD; Ronnett BM; Kurman RJ
Best Pract Res Clin Obstet Gynaecol; 2002 Aug; 16(4):499-512. PubMed ID: 12413931
[TBL] [Abstract][Full Text] [Related]
33. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
34. Pathology of ovarian carcinoma.
Seidman JD; Kurman RJ
Hematol Oncol Clin North Am; 2003 Aug; 17(4):909-25, vii. PubMed ID: 12959182
[TBL] [Abstract][Full Text] [Related]
35. Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives.
Bell DA; Longacre TA; Prat J; Kohn EC; Soslow RA; Ellenson LH; Malpica A; Stoler MH; Kurman RJ
Hum Pathol; 2004 Aug; 35(8):934-48. PubMed ID: 15297961
[TBL] [Abstract][Full Text] [Related]
36. Invasive and noninvasive implants in ovarian serous tumors of low malignant potential.
Michael H; Roth LM
Cancer; 1986 Mar; 57(6):1240-7. PubMed ID: 2417697
[TBL] [Abstract][Full Text] [Related]
37. [Ovarian serous borderline tumor: the prognostic relation to the pathologic features and management].
Zhou XR; Du XG
Zhonghua Fu Chan Ke Za Zhi; 1994 Oct; 29(10):601-3, 637. PubMed ID: 7712874
[TBL] [Abstract][Full Text] [Related]
38. Prognostic factors for recurrence after conservative treatment in a series of 119 patients with stage I serous borderline tumors of the ovary.
Uzan C; Muller E; Kane A; Rey A; Gouy S; Bendiffallah S; Duvillard P; Fauvet R; Darai E; Morice P
Ann Oncol; 2014 Jan; 25(1):166-71. PubMed ID: 24287939
[TBL] [Abstract][Full Text] [Related]
39. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.
Singer G; Stöhr R; Cope L; Dehari R; Hartmann A; Cao DF; Wang TL; Kurman RJ; Shih IeM
Am J Surg Pathol; 2005 Feb; 29(2):218-24. PubMed ID: 15644779
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of the micropapillary pattern in patients with serous borderline ovarian tumors.
Chang SJ; Ryu HS; Chang KH; Yoo SC; Yoon JH
Acta Obstet Gynecol Scand; 2008; 87(4):476-81. PubMed ID: 18382877
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
